The immune checkpoint inhibitors can act on the priming phase when the dendritic cell presents the information to the T cell by blocking the inhibitory signal via CTL4 or in the effector phase when the T cell acts on the melanoma cell by blocking the negative regulation via PD-L1. This evidence concerns the gene CD274 and melanoma.